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# The Author(s) 2019
Abstract
Purpose of Review Informed consent is the integral part of good medical practice in patients with brain tumours. Capacity to
consent may be affected by the brain disorder or its treatment. We intend to draw upon the current neuro-oncology literature to
discuss the influence intracranial tumours have upon patients’ capacity to consent to treatment and research.
Recent Findings We performed a systematic review of studies of capacity to consent for treatment or research in patients with
intracranial tumours. The search retrieved 1597 papers of which 8 were considered eligible for review.
Summary Although there are obvious inherent limitations to solely assessing cognition, most research consistently demonstrated
increased risk of incapacity in brain tumour patients with cognitive impairment. Specific items in cognitive screening batteries,
for example Semantic Verbal Fluency Test (SVFT), Hopkins Verbal Learning Test (HVLT-Recall), and Trail Making Test A/B
(TMT), are simple, easily applied tests that may act as significant red flags to identify patients at increased risk of incapacity and
who subsequently will require additional cognitive/psychiatric evaluation or more formal tests for capacity to consent for
treatment or research.
Keywords Brain tumour . Capacity . Shared decision-making . Legal consent . Glioma . Brainmetastasis
Introduction
Before surgical treatment can take place, informed consent
must be obtained from the adult patient. Informed consent
requires that the patient be an adult and that they receive all
relevant information, in an appropriate format, to enable the
patient to understand, remember, evaluate, and communicate
their decision. The patient must possess the prerequisite men-
tal capacity to come to an autonomous and informed decision
about their care. All adults are assumed to possess the mental
capacity to make medical decisions about their care. Only at
the point an individual demonstrates a deficit in cognition or
disturbed mental state should assessment of their mental ca-
pacity be initiated. At this point, it is the treating physician’s
duty of care to identify and attempt to accommodate the pa-
tient’s ability to understand and retain the relevant information
long enough for them to weigh-up and communicate their
decision. The effects of any underlying condition or side ef-
fects of prior treatment must also be considered. A myriad of
complications from infection to general confusion can cause
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temporary loss of capacity. In cases where it is possible to wait
for these factors to be treated or overcome, such steps should
be taken before obtaining legal consent for surgical proce-
dures. After all appropriate support has been exhausted, if
the patient still cannot make a reasoned decision regarding
the procedure, the patient is considered to have incapacity.
The assessment of incapacity must always remain specific to
both the patient and their given treatment decision. Judgement
of incapacity can change throughout a patient’s illness and
should be seen as a continually evolving set of constructs
(see Mental Capacity Act, 2005 [1]) that may affect medical
decision-making.
Whilst capacity must be assessed on a case-by-case basis,
certain risk factors [2, 3] andmedical conditions are associated
with an increased likelihood of incapacity [4, 5]. The largest
body of literature comes from neurodegenerative and psychi-
atric conditions [6–8], in which disturbance of thought or cog-
nition is often noted alongside incapacity [9]. Patients with
intra-cerebral tumours often present with cognitive impair-
ment from the tumour itself or treatment side effects [10]
and are at a high risk of having incapacity [11].
We have performed a systematic review of studies of ca-
pacity to consent for treatment or research in patients with
brain tumours.
Methods
Literature Searches
A preliminary scoping search (Appendix 1) was conducted to
classify study identifiers to be used in the full systematic re-
view. The scoping search drew 1133 research articles which
were screened by a researcher. The findings from this search
were only used in identifying appropriate parameters for a
detailed literature search and no data were extracted.
The full literature search strategy (Appendix 2) was devel-
oped in conjunction with an information specialist at
Cochrane Neuro-Oncology. The full Embase directory was
used when applying the search strategy yielding 1596 results.
Study Eligibility
After removal of duplicate articles, titles and abstracts of
1586 research articles were initially screened for immedi-
ate inclusion criteria. Due to the relatively limited find-
ings of the scoping search, only two standards were used
to identify papers suited for further assessment: (1) patient
population were adults aged 16 years or older who were
diagnosed with a central nervous system tumour and (2)
capacity to consent to either research or medical treatment
as an outcome measure. Twenty-seven research articles
were identified as eligible for full-text assessment. Upon
full-text assessment, 19 of these papers were deemed in-
eligible (see Fig. 1). Eight full-text articles were included
in the present review. A brief summary of the six studies
we extracted data from is shown in Table 1. Due to the
limited results and variance in methodologies utilised by
researchers, quantitative analyses were not performed.
The Assessment of Mental Capacity
Whilst there is not yet a gold-standard assessment of capacity,
several tools exist to aid assessment [13–15]. Three such as-
sessments are the MacArthur Competence Assessment Tool
for Treatment (MacCAT-T), Competency to Consent to
Treatment Instrument (CCTI), and the Competency to
Consent to Research Instrument (CCRI). The MacCAT-T of-
fers clinicians a semi-structured interview process to ensure all
facets of capacity are discussed and appraised before assess-
ment is made. TheMacCAT-Tutilises the real-world proposed
treatment option with the patient and has seen good clinical
utility in general inpatient, psychiatric, and end-of-life cancer
populations [2, 6, 16]. The CCTI and CCRI on the other hand
offer hypothetical treatment or research vignettes to which a
patient is assessed on their performance across the four con-
structs of capacity (understanding, appreciation, reasoning,
and expression of choice). Whilst the instruments have seen
utility across a range of populations [17, 18] and all three
assessments are deemed substantially more robust than clini-
cian appraisal alone, they all still rely on the clinician’s sub-
jective appraisal of information portrayed by the patient.
Cognitive Assessment
Theorised cognitive underpinnings of capacity [19, 20] have
been compared to standardised cognitive batteries in an at-
tempt to simplify and standardise the binary decision whether
a patient has or does not have capacity to make a decision
around a specific treatment, such as, surgery [21]. Immediate
limitations to using such methods revolve around the duration
of administering detailed neuropsychological assessments.
Instead of in-depth, and often arduous neuropsychological
assessments, abbreviated cognitive batteries have been con-
sidered as potential stand-ins for capacity assessment [22, 23].
The poor sensitivity of the Mini-Mental State Examination
(MMSE) alone limits its use as a formal capacity assessment
[24]. Further, the MMSE lacks sensitivity to executive func-
tions [25, 26], a domain regularly shown to be important when
assessing decision-making and mental capacity [27, 28].
Updated approaches to the rapid assessment of cognitive
status such as the Addenbrooke’s Cognitive Examination
(ACE) and the Montreal Cognitive Assessment (MoCA)
are both considered more sensitive than the MMSE and,
amongst other shared neurocognitive subtests, both include
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brief assessment of executive function. Importantly, the ACE
has been demonstrated as a sensitive test for patients with
brain tumour, when screening for capacity to give consent
prior to surgery compared with the MacCAT-T, performed
by a dual-trained lawyer and neurologist [29]. In this study,
investigating capacity in suspected intracranial tumour pa-
tients found that 25% of patients were found to lack the
mental capacity required to consent to their neurosurgical
treatment. Of particular note, the authors report poor perfor-
mance on the semantic verbal fluency subtest (SVFT—‘how
many animals can you think of in a minute’) to predict
incapacity with 96% sensitivity and 63% specificity. The
addition of a brief cognitive test involving the recall of a
7-item name and address after three attempts to memorise it
increased the sensitivity to 100%, specificity 83%, and 66%
positive predictive value compared with the MacCAT-T.
These subtests, however, should not be seen as a proxy for
capacity assessment [22, 29]. Rather, poor performance on
cognitive assessment should be considered as a ‘red flag’,
mandating a more rigorous capacity assessment.
Mental Capacity in Brain Tumour
The systematic review identified two case control studies
assessing capacity in known primary brain tumour (PBT) pa-
tients following surgery. Patients and controls were consented,
and capacity was assessed using a hypothetical scenario for
treatment. Triebel and colleagues [18] found that compared to
controls, PBT patients were impaired using the CCTI capacity
constructs of reasoning and understanding (35% and 54%,
respectively) and 23% of patients had a compromised con-
struct of appreciation that approached statistical significance
(p = 0.06). Cognitive performance in tests of verbal memory,
semantic fluency, and executive function showed strongest
associations with appreciation. Multivariate analysis indicated
around half of appreciation performance variance was attrib-
utable to Hopkins Verbal Learning Test (HVLT) recognition
discrimination index and animal word fluency test perfor-
mance. Both reasoning and understanding showed strongest
associations with verbal acquisition and recall (HVLT total),
semantic fluency (animal word fluency), and executive func-
tion (Trail Making Test B). Multivariate analysis indicated
Total HVLT performance to account for 33% of patient vari-
ance in reasoning, whereas combined HVLT total and animal
word fluency performance accounted for 72% of the variance
in understanding scores.
When assessing research consent capacity using the CCRI,
understanding appeared once again most commonly impaired
[30]. Unlike treatment consent, more patients were impaired
in appreciation than reasoning (31% and 23%, respectively).
Multivariate analyses suggested semantic word fluency as the
sole predictor for the appreciation standard of the CCRI, ac-
counting for 61% of its variance. Phonemic fluency accounted
for 30% variance in reasoning performance and both phone-
mic fluency and semantic fluency emerged as the two-step
multivariate predictors of understanding, accounting for 71%
of the variance. Again, no such associations were drawn be-
tween any cognitive performance and the consent facet of
expressing a choice.
Fig. 1 Adapted PRISMA flow
diagram [12]
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There are clear similarities between the two studies inves-
tigating primary brain tumours and capacity [18, 30]. Much
like the aforementioned findings of Kerrigan [29] where se-
mantic verbal fluency score ≤ 10 words in a minute was asso-
ciated with lack of capacity to consent for surgery, verbal
memory and verbal fluency offered potential ‘red flags’
whereby poor performance could indicate the need to further
assess capacity.
Three further studies were identified reporting on capacity
in cerebral metastases [31••, 32••, 33•]. Triebel and colleagues
report 61% of all patients diagnosed with brain metastases
showed some form of deficit in capacity (< 1.5 SD below
the mean in one construct area) when assessed within a week
of starting radiotherapy for their brain metastases [33•]. Only
one patient showed impaired expression of treatment choice,
with a further 17% of patients showing impairment in appre-
ciation, 39% in reasoning, and 46% of patients showing some
form of impairment in their ability to understand treatment
decisions. This apparent rank order of incidence likely relates
to the order of complexity each facet assesses [34, 35].
Significant differences between control and patient perfor-
mance were only reported in reasoning and understanding.
In the pair of papers presented by Gerstenecker and col-
leagues, 41 patients with diagnosed brain metastases were
compared against demographically matched controls for cog-
nitive predictors of understanding [31••] and reasoning
Table 1 A brief description of studies and their main findings used in the present review
Study Diagnosis Number
of
patients
Control Capacity
assessment
Test timepoint
(consent)
Main findings
Triebel
et al. [18]
Malignant glioma 26 Yes CCTI Average time from
diagnosis = 6.9
months
Over 50% of patients showed compromised
capacity in medical decision-making.
Cognitive performance on verbal acquisition
and recall, in addition to semantic fluency,
predicted performance of the appreciation,
reasoning, and understanding
standards of consent.
Marson
et al. [30]
Malignant glioma 26 Yes CCRI Average time from
diagnosis = 6.9
months
Malignant glioma patients performed significantly
below the controls on the consent standards of
appreciation, reasoning, and understanding.
Around one-third of patients showed
compromised capacity. Phonemic and semantic
verbal fluency found to predict CCRI
performance.
Kerrigan
et al. [29]
Radiologically
suspected
intracranial tumour
100 No MacCAT-T Preoperative
(no consent
required)
25% of patients lacked mental capacity to give
valid consent to neurosurgery, of which almost
half were missed on initial capacity assessment
by the neurosurgical team. Patients lacking
mental capacity were significantly more
cognitively impaired than those with capacity.
ACE-R semantic verbal fluency performance
and ability to repeat 7-item name and address
after three attempts were predictive of
incapacity.
Gerstenecker
et al. [31••]
Brain metastasis 41 Yes CCTI Within a week
before starting RT
The understanding facet of capacity was
associated with a range of cognitive
performances. Also, performance in phonemic
fluency and verbal memory were found to be
predictors of capacity to understand a treatment
decision.
Gerstenecker
et al. [32••]
Brain metastasis 41 Yes CCTI Within a week
before starting RT
The reasoning facet of capacity shared significant
associations with two cognitive performance
aspects. Also, episodic memory and processing
speed performance were found to be predictive
of capacity to reason through a treatment
decision.
*Patients with a diagnosis of either a primary or metastatic brain tumour were included in the study
Requirements—direct assessment of capacity using either MACCAT-T or CCTR/CCRI
ACE-R, Addenbrooke’s Cognitive Examination-revised; CCRI, Capacity to Consent to Research Instrument; CCTI, Capacity to Consent to Treatment
Instrument; KPS, Karnofsky Performance Scale; MACCAT-T, MacArthur Competence Assessment Tool for Treatment
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through [32••] treatment decisions. Forty-six percent of pa-
tients were found to have impaired understanding, as defined
by a score of ≥ 1.5 standard deviation below control group
average performance. By the same definition, 39% of patients
were found to present impaired decision-making capacity in
reasoning through a treatment decision. The capacity con-
struct of reasoning was also significantly associated with cog-
nitive performance in verbal memory and processing speed.
As such, the researchers were able to report an equation to
predict the likelihood of a patient presenting with impaired
or intact reasoning capacity utilising test scores on both
HVLT Delayed Recall and Trail Making Test A [32••].
Similar associations were also reported in Gerstenecker
et al.’s paper investigating the capacity construct of under-
standing [31••]. As was seen in the reasoning construct, both
delayed recall and trail making tests were significantly asso-
ciated with understanding. In addition to these, several other
cognitive performances were found significant (see Table 2).
Of note, performance in phonemic fluency and HVLT total
score allowed logistic regression predictions to impaired or
intact understanding to be performed.
The Effect of Tumour and Patient Profiles
Tumour Location
No studies identified in the present literature review specifi-
cally investigated the effects of tumour location on capacity.
There is, however, an opportunity to draw indirect associa-
tions from a growing body of literature regarding lesion sites
and their associated cognitive impairment [36, 37]. Mattavelli
and colleagues, for example, report a deficit in cognitive
decision-making in frontal low-grade glioma [38]. Whilst
pragmatically similar, poor performance in a cognitive
decision-making task cannot be translated to poor medical
decision-making without formal capacity assessment. Due to
theorised higher order cognitive underpinnings of capacity
[20, 29, 39, 40], constructs of capacity are unlikely attributable
to any one specific neural location nor tumour site. Instead, it
is much more conceivable that damage to any number of lo-
cations associated with that cognitive function and in turn
capacity performance to manifest in impairment.
Tumour Grade
Patients with low-grade glioma most commonly present with
seizures, whilst those with high-grade gliomamore commonly
present with focal neurological or cognitive deficits and head-
ache associated with raised intracranial pressure. More recent-
ly, tumour grade has been considered more important with
respect to neurocognitive abilities than tumour volume, sei-
zure status, or concomitant medication in newly diagnosed
glioma [41, 42]. Kerrigan and colleagues reported the inci-
dence of incapacity in relation to WHO tumour grade [11,
29]. Lack of capacity to consent was associated with glioblas-
toma suggesting that the rapid tumour growth may affect
neurocognitive performance by limiting the extent neuro-
plasticity can accommodate lesion-based changes in the brain
[36, 43]. Importantly, cognitive functions found by Noll et al.
to be influenced by tumour grade were in line with those
associated with capacity, specifically, verbal learning, execu-
tive function, and language ability [41]. Such associations
specifically in the context of capacity assessment warrant fur-
ther investigation with the intent of uncovering additional risk
factors to the cognitive red flags described earlier.
Table 2 A summary of statistically significant regression analyses as reported in reviewed research
Capacity function Author (year) Patient sample Statistical analysis Cognitive test Statistic/significance
Appreciation Triebel et al. [18] Malignant glioma Stepwise regression HVLT-RDI
Animal fluency
R2 = 0.50***
R2 = 0.58*
Marson et al. [30] Malignant glioma Stepwise regression Animal fluency R2 = 0.62***
Reasoning Triebal et al. [18] Malignant glioma Stepwise regression HVLT trials 1–3 R2 = 0.36***
Marson et al. [30] Malignant glioma Stepwise regression Letter fluency R2 = 0.34**
Gerstenecker et al. [32••] Brain metastases Linear regression HVLT delayed and TMTA R2 = 0.18*
Understanding Triebal et al. [18] Malignant glioma Stepwise regression HVLT trials 1–3
Animal fluency
Trial B
R2 = 0.68***
R2 = 0.75*
r = − 0.79**
Marson et al. [30] Malignant glioma Stepwise regression Letter fluency
Animal fluency
R2 = 0.64***
R2 = 0.73***
Gerstenecker et al. [31••] Brain metastases Stepwise regression HVLT total
HVLT total and phonemic fluency
R2 = 0.58***
R2 = 0.68***
Significance levels: *p ≤ .05, **p ≤ .01, ***p ≤ .001
All R2 reported are cumulative, not adjusted
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Effects of Treatment
The effect of surgery on a patient’s capacity to consent to
subsequent treatments is likely an area of substantial in-
terest due to the potential of side effects and relatively
short interlude between follow-up treatments [37]. With
respect to subsequent treatments, only one study reported
the frequency of incapacity in relation to their treatment
[32••]. No significant differences were seen between radi-
ation and chemotherapy and no correction was made to
account for patients who had both treatments. The limited
data currently available leave this question open for fur-
ther study. It is likely that both treatments have at least a
transient effect on cognition [44] with the impact and
duration of side effects often varying between treatment
approaches [45–47], their influence on capacity may also
be transient in nature. There are, however, increasing con-
cerns over the persistence of cognitive impairment expe-
rienced following whole brain radiation therapy; as such,
treatment fields and dose should be considered when
making capacity assessment. There is growing evidence
that hippocampal avoidance techniques may limit future
cognitive impairment [48–50] and such techniques should
be considered in reference to treatment influence on
capacity.
Only one study reviewed reported on associations between
current medication use and mental capacity. Marson et al.
(2010) found that corticosteroid use was significantly associ-
ated with impaired capacity for appreciation, reasoning, and
understanding [30]. Anticonvulsant medication was also asso-
ciated with reasoning and understanding, although to a lesser
extent. From the data presented by Marson and colleagues, it
is impossible to say whether this finding is indicative of the
drugs themselves or the underlying symptoms the drugs are
aimed at combatting. Corticosteroids, for example, are regu-
larly used to treat oedema and its associated neurological
symptoms which can often manifest in cognitive disturbance
[51, 52]. Anticonvulsants, on the other hand, are prescribed to
manage seizures, and side effects can often involve distur-
bance in personality, cognition, or fatigue [53]; however, the
limited findings warrant further investigation.
Effect of Performance Status
The Karnofsky Performance Scale (KPS) is a scale regularly
used in oncology to record the disability of a cancer patient
[54]. In a mixed sample of primary and secondary brain tu-
mour patients, Martin and colleagues investigated the relation-
ship between KPS and CCTI performance [55]. Significant
differences in performance on scales of appreciation and un-
derstanding were noted between patients with KPS scores of
90–100 and 70–80. Almost half of patients with KPS ≥ 90 and
only 23% of patients with a KPS of 70–80 scored within
normal range in all constructs of the CCTI. The high frequen-
cy of scores below 1.5 standard deviations from mean in at
least one construct of the CCTI limits the clinical utility of
using the KPS as a red flag for incapacity.
Effect of Emotion
Across all research reviewed, age, gender, time since diag-
nosis, or depression did not appear to have a significant
influence upon capacity. Only one paper suggested years
of education and gender to have an association with capac-
ity in brain tumour patients [29]. Mood assessment in all
studies was brief and the lack of associations between de-
pressive symptoms and incapacity is perhaps unusual, as
depression is often seen to influence the information pro-
cessing speed [56] and subsequent decision-making [57].
Kerrigan et al. report poor tolerance towards completing
the Hospital Anxiety and Depression Scale (HADS), a rel-
atively brief patient-reported outcome measure (PROM)
[29]. Sixty-eight percent of patients who were found not
to have capacity to consent to surgery using the MacCAT-T
assessment were unable to complete the HADS satisfacto-
rily. A further 13% of patients with capacity were also
unable to adequately complete the test. Due to the more
inclusive sampling technique used by Kerrigan and col-
leagues [29], such findings may be more indicative of gen-
eralised brain tumour patients’ ability to use self-report
items than by other researchers in this review and explain
the low influence of mood throughout the review findings.
Alternatively, it is possible that mood scores were general-
ly low across all patients and no clear association between
mood and capacity could be identified. Therefore, assess-
ment of mood should be evaluated in addition to capacity
as depression is often considered a concern in regard to a
patient’s capacity [58].
Suitable, simple, and clear presentation of information dur-
ing shared decision-making has been proven to reduce anxiety
of glioma patients prior to treatment [59]. Although simple
plain language explanations should be common practice in
modern medicine, a review of information needs in patients
of brain tumour reveals otherwise [60]. The present review
identified only one study investigating brain tumour patients’
capacity to consent to research. Due to the relatively poor
outcomes of interventions available to brain tumour patients,
the increasing number of clinical trials and more complex trial
designs and consent forms, patients may be ‘at-risk’ of being
exploited for their participation [61]. Ibrahim and colleagues
report patients being fought over for their participation in clin-
ical research [62], with coercion a possible occurrence of such
research [63]. Patients may show a preconceived preference to
active treatment over wait-and-see proposals regardless of
evidence-based clinician guidance [64].
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As illustrated by Kerrigan et al. the tolerability of certain
PROMs is another element to consider when investigating
brain tumour patients, particularly those with impaired capac-
ity [29]. If a relatively brief and simple PROM, such as the
HADS, is poorly tolerated in brain tumour patients prior to
surgical intervention, more detailed and demanding PROMs
are likely also heavily influenced in this population. When a
patient is identified as lacking capacity during a study, re-
searchers must make the decision as to whether or not com-
pleted PROM data are reliable. As illustrated in the present
review, patients lacking capacity have the potential to make up
a significant proportion of the patient population and ethically,
one must consider whether continued participation in a trial is
justified. Patient-proxy or observer-reported outcomes are
gaining traction in clinical trials where the reliability of
PROMs is brought to question.
Conclusion
Medical decision-making capacity remains under assessed
in neuro-oncology. Many of the studies trying to under-
stand what influences capacity have focused on identifying
possible cognitive links. However, cognitive performance
cannot be used as a capacity test stand-in. Certain assess-
ments, such as the SVFT, HVLT-R, and TMTA/B, may be
useful in ‘flagging’ patients that may require further neu-
ropsychological assessment. When considering the
Kerrigan et al. [29] and Sullivan et al. [21] studies, it is
clear that identifying those patients in need of a more de-
tailed assessment is far more beneficial than evaluating all
patients in a detailed manner. The use of ROC analysis to
infer clinical utility of cognitive test performance in iden-
tifying patients who may require further assessment of ca-
pacity is more robust than correlation analysis alone.
Whilst regression analyses used in Gerstenecker and col-
league’s research [31••, 32••] offer statistical predictions of
incapacity in brain tumour populations, the utility of this in
real-world clinical settings may be more limited. The au-
thors propose it is of greater benefit to identify rapid means
of assessment than it is to present statistical models to
which patient data can be imputed.
Whilst there is limited literature to suggest an influence
of tumour type, grade, or location on capacity, there is a
recurring theme across numerous studies suggesting tu-
mour characteristics’ influences on cognitive abilities
such as verbal fluency, memory, and executive function.
Likewise, there is a limited literature to suggest any ther-
apeutic or medicinal influences on the longitudinal effects
of capacity throughout the treatment process. This is of
particular importance in the brain tumour population due
to the extent of treatment that is required throughout their
disease trajectory. Finally, the effect of emotion on
medical decision-making is poorly understood. A clini-
cian’s duty of care should remain and serve to offer im-
partial advice on all treatment and research options
available.
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Appendix 1. Scoping search strategy
1. Exp INFORMED CONSENT/
2. Exp Presumed Consent/
3. Exp mental Competency
4. 1 or 2 or 3
5. Neoplasms/ or exp nervous system neoplasms/
6. 4 and 5
Appendix 2. Embase search strategy
1. exp informed consent/
2. (informed adj2 (consent or decision* or choice*)).tw.
3. informed decision making.tw.
4. informed choice.tw.
5. (consent* adj (process or form* or document*)).tw.
6. consent process.tw.
7. consent*.tw.
8. (improv* adj2 consent).tw.
9. (understanding adj2 consent).tw.
10. presumed consent.mp.
11. exp mental capacity/
12. ((competen* or capacity*) adj5 (consent* or decision*
or choice*)).tw.
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. exp central nervous system tumor/
15. ((central nervous system or CNS or brain* or cerebral*
or intracerebral or intra-cerebral or intracranial or intra-
cranial or spine or spinal or astrocytic or oligodendrog-
lial or ependymal) adj5 (cancer* or tumor* or tumour*
or malignan* or neoplas* or carcinoma*)).tw.
16. exp neuroepithelioma/
17. ((glioneural or neuroectodermal or embryonal or
neuroepithelial or pineal or choroid plexus or teratoid
or rhabdoid) adj5 (tumor* or tumour*)).tw.
18. (glioma* or glial* or astrocytoma* or xanthoastrocytoma*
or glioblastoma* or gliosarcoma* or oligodendrogli* or
oligoastrocyt* or ependym* or subependym* or
astroblastoma* or ganglioglioma* or gangliocytoma* or
neurocytoma* or liponeurocytoma* or pineocytoma* or
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pineoblastoma* or medulloblastoma* or neuroblastoma*
or ganglioneuroblastoma*or medulloepithelioma* or
GBM*).tw.
19. 14 or 15 or 16 or 17 or 18
20. 13 and 19
21. limit 20 to embase
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